Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 1035-1040

  Tural, Deniz ^a   Selcukbiricik, Fatih ^a   Erdamar, Sibel ^b   Ozkurt, Canan Unlu ^b   Yanmaz, Teoman ^a   Mandel, Nil Molinas ^a   Serdengeçti, Suḧeyla ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antineoplastic combined chemotherapy protocols; Cetuximab; Colorectal neoplasms; Epidermal growth factor receptor; Mutation

Indexed keywords

CETUXIMAB; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; ONCOGENE K RAS G13D; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 84885755854     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12983     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Alberts SR, Wagman LD: Chemotherapy for colorectal cancer liver metastases.
3. Oncologist 2008; 13:1063-1073.
4. Van Cutsem E, Könne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
5. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345. (Pubitemid 38944402)
6. Van Cutsem E, Könne CH, Láng I, et al.: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-2019.
7. Normanno N, Tejpar S, Morgilio F, De Luca A, Van Cutsem E, Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6:519-527.
8. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-2648. (Pubitemid 46548951)
9. Frattini M, Saletti P, Romagnani E, et al.: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-1145. (Pubitemid 47587019)
10. Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6:279-286. (Pubitemid 40590264)
11. Guerrero S, Casanova I, Farré L, Mazo A, Capella G, Manques R: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000; 60:6750-6756.
12. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-1820.
13. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012 Jun 25. (Epub ahead of print)
14. Gajate P, Sastre J, Bando I, et al.: Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2012 Apr 24. (Epub ahead of print)
15. Peeters M, Douillard J, Van Cutsem E, et al.: Evaluation of individual codon 12 and 13 mutant KRAS alleles as prognostic and predictive biomarkers of response to panitumumab in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2012; 30 (suppl 4; abstr 383).
16. Douillard JY, Siena S, Cassidy J, et al.: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-4705.